NasdaqGS:DYNBiotechs
Dyne Therapeutics (DYN) Could Be 38% Undervalued As FDA Milestones Lift Pipeline Hopes
Dyne Therapeutics (DYN) has been in focus after back to back U.S. FDA milestones, including clearance to begin a Phase 1 trial for DYNE-302 and Priority Review for Duchenne candidate DYNE-251.
See our latest analysis for Dyne Therapeutics.
Recent regulatory milestones appear to be feeding into Dyne Therapeutics' share price momentum, with the stock at US$25.18 after a 15.56% 30 day share price return and a 150.55% 1 year total shareholder return, even as recent losses and the July follow on...